公开(公告)号：US06863886B2

公开(公告)日：2005-03-08

申请号：US10371850

申请日：2003-02-21

申请人： Hampar Karageozian ,  Vicken Karageozian ,  Maria C. Kenney ,  Jose L. G. Flores ,  Gabriel Arturo Carpio Aragon ,  Anthony B. Nesburn

发明人： Hampar Karageozian ,  Vicken Karageozian ,  Maria C. Kenney ,  Jose L. G. Flores ,  Gabriel Arturo Carpio Aragon ,  Anthony B. Nesburn

IPC分类号： A61K38/46 ,  A61K38/47 ,  A61K38/51 ,  A61K38/43

CPC分类号： A61K38/47 ,  Y10S514/912

摘要： An enzymatic method is provided for treating ophthalmic disorders of the mammalian eye. Prevention of neovascularization and the increased rate of clearance from the vitreous of materials toxic to retina is accomplished by administering an amount of hyaluronidase effective to liquefy the vitreous humor of the treated eye without causing toxic damage to the eye. Liquefaction of the vitreous humor increases the rate of liquid exchange from the vitreal chamber. This increase in exchange removes those materials and conditions whose presence causes ophthalmological and retinal damage.

公开(公告)号：US20070105950A1

公开(公告)日：2007-05-10

申请号：US11585400

申请日：2006-10-23

申请人： Vicken Karageozian ,  David Castillejos ,  John Park

发明人： Vicken Karageozian ,  David Castillejos ,  John Park

IPC分类号： A61K31/343 ,  A61K31/17

CPC分类号： A61K31/17 ,  A61K31/155 ,  A61K31/343 ,  A61K31/40 ,  A61K2300/00

摘要： Methods for treating disorders of the eye and/or disorders of a nerve in a human or veterinary patient by delivering to the patient a therapeutically effective amount of a compound selected from the group of; urea, urea derivatives, thiourea, thiourea derivatives, guanidine, guanidine derivatives and compounds having General Formula I as set forth herein. For ophthalmic applications, the compound may be delivered by intravitreal injection such that the compound causes vitreal liquefaction, posterior vitreoretinal detachment and other affects.

摘要翻译： 用于通过向患者递送治疗有效量的选自以下的化合物的方法来治疗人或兽医患者的眼睛疾病和/或神经障碍： 脲，脲衍生物，硫脲，硫脲衍生物，胍，胍衍生物和具有本文所述通式I的化合物。 对于眼科应用，化合物可以通过玻璃体内注射递送，使得该化合物引起玻璃体液化，后玻璃体视网膜脱离和其它影响。

公开(公告)号：US20050069531A1

公开(公告)日：2005-03-31

申请号：US10987483

申请日：2004-11-12

申请人： Hampar Karageozian ,  Vicken Karageozian ,  Maria Kenney ,  Jose Flores ,  Gabriel Carpio Aragon ,  Anthony Nesburn

发明人： Hampar Karageozian ,  Vicken Karageozian ,  Maria Kenney ,  Jose Flores ,  Gabriel Carpio Aragon ,  Anthony Nesburn

IPC分类号： A61K38/46 ,  A61K38/47 ,  A61K38/51

CPC分类号： A61K38/47 ,  Y10S514/912

摘要： An enzymatic method is provided for treating ophthalmic disorders of the mammalian eye. Prevention of neovascularization and the increased rate of clearance from the vitreous of materials toxic to retina is accomplished by administering an amount of hyaluronidase effective to liquefy the vitreous humor of the treated eye without causing toxic damage to the eye. Liquefaction of the vitreous humor increases the rate of liquid exchange from the vitreal chamber. This increase in exchange removes those materials and conditions whose presence causes ophthalmological and retinal damage.

摘要翻译： 提供了一种用于治疗哺乳动物眼睛眼部疾病的酶法。 通过给予一定量的透明质酸酶来有效地液化治疗眼睛的玻璃体液而不会对眼睛造成毒性损伤来实现预防新生血管形成和对视网膜毒性玻璃体的清除率的提高。 玻璃体液的液化增加了玻璃体腔液体的交换速度。 这种交换的增加消除了那些存在导致眼科和视网膜损伤的材料和条件。

公开(公告)号：US06610292B2

公开(公告)日：2003-08-26

申请号：US09444003

申请日：1999-11-19

申请人： Hampar Karageozian ,  Vicken Karageozian ,  Maria C. Kenney ,  Jose L. G. Flores ,  Gabriel Arturo Carpio Aragon ,  Anthony B. Nesburn

发明人： Hampar Karageozian ,  Vicken Karageozian ,  Maria C. Kenney ,  Jose L. G. Flores ,  Gabriel Arturo Carpio Aragon ,  Anthony B. Nesburn

IPC分类号： A61K3846

CPC分类号： A61K38/47 ,  Y10S514/912

摘要： An enzymatic method is provided for treating ophthalmic disorders of the mammalian eye. Prevention of neovascularization and the increased rate of clearance from the vitreous of materials toxic to the retina is accomplished by administering an amount of hyaluronidase effective to liquefy the vitreous humor of the treated eye without causing toxic damage to the eye. Liquefaction of the vitreous humor increases the rate of liquid exchange from the vitreal chamber. This increase in exchange removes those materials and conditions whose presence causes ophthalmological and retinal damage.

摘要翻译： 提供了一种用于治疗哺乳动物眼睛眼部疾病的酶法。 预防新生血管形成和从对视网膜有毒的材料的玻璃体中的清除率提高是通过施用一定量的透明质酸酶来有效地液化经处理的眼睛的玻璃体液而不引起眼睛的毒性损伤来实现的。 玻璃体液的液化增加了玻璃体腔液体的交换速度。 这种交换的增加消除了那些存在导致眼科和视网膜损伤的材料和条件。

公开(公告)号：US20060034822A1

公开(公告)日：2006-02-16

申请号：US11204636

申请日：2005-08-15

申请人： Hampar Karageozian ,  Vicken Karageozian ,  Maria Kenney ,  Jose Gutierrez Flores ,  Gabriel Carpio Aragon ,  Anthony Nesburn

发明人： Hampar Karageozian ,  Vicken Karageozian ,  Maria Kenney ,  Jose Gutierrez Flores ,  Gabriel Carpio Aragon ,  Anthony Nesburn

IPC分类号： A61K38/47 ,  A61K38/46 ,  A61K38/48

CPC分类号： A61K38/47 ,  A61K31/7016 ,  Y10S514/912 ,  A61K2300/00

摘要： A thimerosal-free hyaluronidase preparation wherein the preferred hyaluronidase enzyme is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,000 MW. Also disclosed is a method for accelerating the clearance of hemorrhagic blood from the vitreous humor of the eye, said method comprising the step of contacting at least one hemorrhage-clearing enzyme (e.g., a β-glucuronidase, matrix metalloproteinase, chondroitinase, chondroitin sulfatase or protein kinase) with the vitreous humor in an amount which is effective to cause accelerated clearance of blood therefrom.

摘要翻译： 不含硫柳汞的透明质酸酶制剂，其中优选的透明质酸酶酶的分子量分数低于40,000MW，在60-70,000MW和高于100,000MW之间。 还公开了一种用于加速来自眼睛玻璃体液的出血血清除的方法，所述方法包括使至少一种出血清除酶（例如，β-葡糖醛酸糖苷酶，基质金属蛋白酶，软骨素酶，软骨素硫酸酯酶或 蛋白激酶），其玻璃体液的量可以有效地引起血液的快速清除。

公开(公告)号：US06537545B1

公开(公告)日：2003-03-25

申请号：US09656849

申请日：2000-09-07

申请人： Hamper Karageozian ,  John Y. Park ,  Vicken Karageozian ,  Phillip Baker ,  Anthony Nesburn

发明人： Hamper Karageozian ,  John Y. Park ,  Vicken Karageozian ,  Phillip Baker ,  Anthony Nesburn

IPC分类号： A61K3844

CPC分类号： G02C7/047 ,  A61F2/147 ,  A61F9/0017 ,  A61F9/013 ,  A61K9/0048 ,  A61L27/50 ,  A61L2430/16

摘要： An Enzyme Orthokeratology method is provided for correcting refractive errors in the eye of a subject mammal. Accelerating reshaping of the cornea is accomplished by administering a corneal hardening amount of a corneal hardening agent to the eye of the subject. Reformation is accomplished under the influence of a rigid contact lens or a series of lenses having a concave curvature that will correct a refractive error. The cornea rapidly reshapes its convex curvature to the concave curvature of the contact lens, rendering the eye emmetropic. The cornea is permitted to “harden” to retain the new emmetropic shape. After “hardening” has occurred, the lens rendering the eye emmetropic is removed.

摘要翻译： 提供了一种用于校正受试哺乳动物眼睛中的屈光不正的酶角膜矫正方法。 通过将角膜硬化量的角膜硬化剂施用于受试者的眼睛来实现加速角膜整形。 在刚性隐形眼镜或具有校正折射误差的凹曲率的一系列透镜的影响下完成改造。 角膜迅速将其凸曲率重新形成隐形眼镜的凹曲面，使眼睛正视。 允许角膜“硬化”以保持新的正视形状。 在“硬化”发生之后，去除眼睛正视的镜片。